Radiation therapy is an effective modality in the treatment of mantle cell lymphoma, even in heavily pretreated patients

Waqar Haque, Khinh Voong, Ferial Shihadeh, Isidora Arzu, Chelsea Pinnix, Ali Mazloom, L. Jeffrey Medeiros, Jorge Romaguera, Alma Rodriguez, Michael Wang, Pamela Allen, Bouthaina Dabaja

Research output: Contribution to journalArticle

Abstract

Radiotherapy (RT) is an effective modality in heavily pretreated and chemorefractory patients with mantle cell lymphoma. Low dose radiation offered palliation in 95% of patients, 92% of treated sites showed complete response to RT. Introduction: Mantle cell lymphoma has an aggressive clinical course and continuous relapse pattern with a median survival of 3 to 7 years. Multiple courses of chemotherapy are the basis of treatment. Radiotherapy is underutilized in this disease. We undertook this study to assess the role of radiation therapy . Materials and Methods: A total of 41 consecutive patients with mantle cell lymphoma diagnosed from December, 1999 to January, 2010 who received radiation therapy were reviewed retrospectively. The main endpoint was in-field lymphoma response at each irradiated disease site . Results: There were 39 evaluable patients (68 symptomatic sites). Sites treated included: nodal stations (n = 31), soft tissue (n = 13), mucosal sites (n = 11), central nervous system (n = 10), gastrointestinal tract (n = 2), and bone (n = 1). Median maximum tumor size at presentation was 3.5 cm (range, 1.3 cm-9.6 cm). The median dose of radiation was 30.6 Gy (range 18-40 Gy). Median follow-up post radiation per site was 12.3 months (range, 0.6-80.9 months). Response to treatment was complete in 47 sites (69.1%), partial in 16 sites (23.5%), and 5 sites (7.4%) had stable disease. In 9 (13.2%) sites local relapse occurred (median 7 months; range 2-21). The mean size of lymphoma at time of RT correlated with relapse, with tumors with local relapse larger than those without a local relapse (P = .005) . Conclusions: Our data add to accumulating evidence that mantle cell lymphoma is a radio-sensitive disease with excellent responses to relatively low radiation doses, even in patients with chemo-refractory disease .

Original languageEnglish (US)
Pages (from-to)474-479
Number of pages6
JournalClinical Lymphoma, Myeloma and Leukemia
Volume14
Issue number6
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Mantle-Cell Lymphoma
Radiotherapy
Recurrence
Radiation
Lymphoma
Therapeutics
Radio
Gastrointestinal Tract
Neoplasms
Central Nervous System
Bone and Bones
Drug Therapy
Survival

Keywords

  • Chemotherapy
  • In-field response
  • Refractory disease
  • Relapse
  • Site-specific treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Radiation therapy is an effective modality in the treatment of mantle cell lymphoma, even in heavily pretreated patients. / Haque, Waqar; Voong, Khinh; Shihadeh, Ferial; Arzu, Isidora; Pinnix, Chelsea; Mazloom, Ali; Medeiros, L. Jeffrey; Romaguera, Jorge; Rodriguez, Alma; Wang, Michael; Allen, Pamela; Dabaja, Bouthaina.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 14, No. 6, 2014, p. 474-479.

Research output: Contribution to journalArticle

Haque, W, Voong, K, Shihadeh, F, Arzu, I, Pinnix, C, Mazloom, A, Medeiros, LJ, Romaguera, J, Rodriguez, A, Wang, M, Allen, P & Dabaja, B 2014, 'Radiation therapy is an effective modality in the treatment of mantle cell lymphoma, even in heavily pretreated patients', Clinical Lymphoma, Myeloma and Leukemia, vol. 14, no. 6, pp. 474-479. https://doi.org/10.1016/j.clml.2014.07.003
Haque, Waqar ; Voong, Khinh ; Shihadeh, Ferial ; Arzu, Isidora ; Pinnix, Chelsea ; Mazloom, Ali ; Medeiros, L. Jeffrey ; Romaguera, Jorge ; Rodriguez, Alma ; Wang, Michael ; Allen, Pamela ; Dabaja, Bouthaina. / Radiation therapy is an effective modality in the treatment of mantle cell lymphoma, even in heavily pretreated patients. In: Clinical Lymphoma, Myeloma and Leukemia. 2014 ; Vol. 14, No. 6. pp. 474-479.
@article{49f284cbb83b4e45bfedf6270c2cf828,
title = "Radiation therapy is an effective modality in the treatment of mantle cell lymphoma, even in heavily pretreated patients",
abstract = "Radiotherapy (RT) is an effective modality in heavily pretreated and chemorefractory patients with mantle cell lymphoma. Low dose radiation offered palliation in 95{\%} of patients, 92{\%} of treated sites showed complete response to RT. Introduction: Mantle cell lymphoma has an aggressive clinical course and continuous relapse pattern with a median survival of 3 to 7 years. Multiple courses of chemotherapy are the basis of treatment. Radiotherapy is underutilized in this disease. We undertook this study to assess the role of radiation therapy . Materials and Methods: A total of 41 consecutive patients with mantle cell lymphoma diagnosed from December, 1999 to January, 2010 who received radiation therapy were reviewed retrospectively. The main endpoint was in-field lymphoma response at each irradiated disease site . Results: There were 39 evaluable patients (68 symptomatic sites). Sites treated included: nodal stations (n = 31), soft tissue (n = 13), mucosal sites (n = 11), central nervous system (n = 10), gastrointestinal tract (n = 2), and bone (n = 1). Median maximum tumor size at presentation was 3.5 cm (range, 1.3 cm-9.6 cm). The median dose of radiation was 30.6 Gy (range 18-40 Gy). Median follow-up post radiation per site was 12.3 months (range, 0.6-80.9 months). Response to treatment was complete in 47 sites (69.1{\%}), partial in 16 sites (23.5{\%}), and 5 sites (7.4{\%}) had stable disease. In 9 (13.2{\%}) sites local relapse occurred (median 7 months; range 2-21). The mean size of lymphoma at time of RT correlated with relapse, with tumors with local relapse larger than those without a local relapse (P = .005) . Conclusions: Our data add to accumulating evidence that mantle cell lymphoma is a radio-sensitive disease with excellent responses to relatively low radiation doses, even in patients with chemo-refractory disease .",
keywords = "Chemotherapy, In-field response, Refractory disease, Relapse, Site-specific treatment",
author = "Waqar Haque and Khinh Voong and Ferial Shihadeh and Isidora Arzu and Chelsea Pinnix and Ali Mazloom and Medeiros, {L. Jeffrey} and Jorge Romaguera and Alma Rodriguez and Michael Wang and Pamela Allen and Bouthaina Dabaja",
year = "2014",
doi = "10.1016/j.clml.2014.07.003",
language = "English (US)",
volume = "14",
pages = "474--479",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "6",

}

TY - JOUR

T1 - Radiation therapy is an effective modality in the treatment of mantle cell lymphoma, even in heavily pretreated patients

AU - Haque, Waqar

AU - Voong, Khinh

AU - Shihadeh, Ferial

AU - Arzu, Isidora

AU - Pinnix, Chelsea

AU - Mazloom, Ali

AU - Medeiros, L. Jeffrey

AU - Romaguera, Jorge

AU - Rodriguez, Alma

AU - Wang, Michael

AU - Allen, Pamela

AU - Dabaja, Bouthaina

PY - 2014

Y1 - 2014

N2 - Radiotherapy (RT) is an effective modality in heavily pretreated and chemorefractory patients with mantle cell lymphoma. Low dose radiation offered palliation in 95% of patients, 92% of treated sites showed complete response to RT. Introduction: Mantle cell lymphoma has an aggressive clinical course and continuous relapse pattern with a median survival of 3 to 7 years. Multiple courses of chemotherapy are the basis of treatment. Radiotherapy is underutilized in this disease. We undertook this study to assess the role of radiation therapy . Materials and Methods: A total of 41 consecutive patients with mantle cell lymphoma diagnosed from December, 1999 to January, 2010 who received radiation therapy were reviewed retrospectively. The main endpoint was in-field lymphoma response at each irradiated disease site . Results: There were 39 evaluable patients (68 symptomatic sites). Sites treated included: nodal stations (n = 31), soft tissue (n = 13), mucosal sites (n = 11), central nervous system (n = 10), gastrointestinal tract (n = 2), and bone (n = 1). Median maximum tumor size at presentation was 3.5 cm (range, 1.3 cm-9.6 cm). The median dose of radiation was 30.6 Gy (range 18-40 Gy). Median follow-up post radiation per site was 12.3 months (range, 0.6-80.9 months). Response to treatment was complete in 47 sites (69.1%), partial in 16 sites (23.5%), and 5 sites (7.4%) had stable disease. In 9 (13.2%) sites local relapse occurred (median 7 months; range 2-21). The mean size of lymphoma at time of RT correlated with relapse, with tumors with local relapse larger than those without a local relapse (P = .005) . Conclusions: Our data add to accumulating evidence that mantle cell lymphoma is a radio-sensitive disease with excellent responses to relatively low radiation doses, even in patients with chemo-refractory disease .

AB - Radiotherapy (RT) is an effective modality in heavily pretreated and chemorefractory patients with mantle cell lymphoma. Low dose radiation offered palliation in 95% of patients, 92% of treated sites showed complete response to RT. Introduction: Mantle cell lymphoma has an aggressive clinical course and continuous relapse pattern with a median survival of 3 to 7 years. Multiple courses of chemotherapy are the basis of treatment. Radiotherapy is underutilized in this disease. We undertook this study to assess the role of radiation therapy . Materials and Methods: A total of 41 consecutive patients with mantle cell lymphoma diagnosed from December, 1999 to January, 2010 who received radiation therapy were reviewed retrospectively. The main endpoint was in-field lymphoma response at each irradiated disease site . Results: There were 39 evaluable patients (68 symptomatic sites). Sites treated included: nodal stations (n = 31), soft tissue (n = 13), mucosal sites (n = 11), central nervous system (n = 10), gastrointestinal tract (n = 2), and bone (n = 1). Median maximum tumor size at presentation was 3.5 cm (range, 1.3 cm-9.6 cm). The median dose of radiation was 30.6 Gy (range 18-40 Gy). Median follow-up post radiation per site was 12.3 months (range, 0.6-80.9 months). Response to treatment was complete in 47 sites (69.1%), partial in 16 sites (23.5%), and 5 sites (7.4%) had stable disease. In 9 (13.2%) sites local relapse occurred (median 7 months; range 2-21). The mean size of lymphoma at time of RT correlated with relapse, with tumors with local relapse larger than those without a local relapse (P = .005) . Conclusions: Our data add to accumulating evidence that mantle cell lymphoma is a radio-sensitive disease with excellent responses to relatively low radiation doses, even in patients with chemo-refractory disease .

KW - Chemotherapy

KW - In-field response

KW - Refractory disease

KW - Relapse

KW - Site-specific treatment

UR - http://www.scopus.com/inward/record.url?scp=84922611630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922611630&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2014.07.003

DO - 10.1016/j.clml.2014.07.003

M3 - Article

C2 - 25108680

AN - SCOPUS:84922611630

VL - 14

SP - 474

EP - 479

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 6

ER -